CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell $50,000,000 of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriter a 30-day option to purchase up to an additional $7,500,000 of shares of its common stock. All of the shares in the offering are to be sold by Editas Medicine.

Morgan Stanley is acting as sole book running manager for the offering.

About Editas Medicine

Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.